CareLit Fachartikel

Multiomic approach to determine prognosis for patients with HER2-positive breast cancer

PA Fasching, S Rabizadeh, F Cecchi, MW Beckmann, SY Brucker, J Golovato, A Hartmann, T Hembrough, W Janni, B Rack, Z Sanborn, A Schneeweiss, CJ Vaske, P Soon-Shiong, S Benz · Senologie - Zeitschrift für Mammadiagnostik und -therapie · 2016 · Heft 04

Dokument
1022831
CareLit-ID
Jahr
2016
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Senologie - Zeitschrift für Mammadiagnostik und -therapie
Autor:innen
PA Fasching, S Rabizadeh, F Cecchi, MW Beckmann, SY Brucker, J Golovato, A Hartmann, T Hembrough, W Janni, B Rack, Z Sanborn, A Schneeweiss, CJ Vaske, P Soon-Shiong, S Benz
Ausgabe
Heft 04 / 2016
Seiten
–
Erschienen: 2016-04-26 00:00:00
ISSN
1611-6453
DOI
10.1055/s-0036-1583344

Zusammenfassung

Objectives: Despite improvements in the treatment of HER2-positive breast cancer (BC), almost all patients progress in the metastatic setting. We conducted the GPS Cancer test (the first CAP accredited and CLIA certified, integrated, multiomic test utilizing whole genome sequencing (WGS), RNA sequencing (RNAseq), quantitative proteomics, and pathway analysis to determine associations between tumor molecular profiles and recurrence/metastases among HER2-positive patients. Methodology: Patients were enrolled in the SUCCESS A, SUCCESS B, and PRAEGNANT studies. Fifty-nine patients selected for analysis were divided…

Schlagworte

Senologie - Zeitschrift für Mammadiagnostik und -therapie